Amicus rises as EU health regulator backs muscle disorder therapy

Amicus Therapeutics

16/12/2022 18:22

** Shares of Amicus Therapeutics Inc  FOLD.O  rise 2.7% at
$12.41 
    ** EU's health regulator said it had recommended granting
marketing authorization for co's experimental therapy to treat
Pompe disease, a muscle disorder
    ** The recommendation from the European Medicines Agency
comes amid delays for the drug in the United States 
    ** The U.S. FDA extended the drug's review in October, for
the second time, citing COVID-related travel curbs as reason in
delay 
    ** The regulators decision only applies to co's lab-made
protein cipaglucosidase alfa, used in combination with another
drug, miglustat
        ** Co expects a recommendation on miglustat in Q2 2023
    ** Including session gains, Amicus stock up 7.5% YTD 
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))